Work

Supplementary Table S3 from Phase Ib Clinical and Pharmacodynamic Study of the TIE2 Kinase Inhibitor Rebastinib with Paclitaxel or Eribulin in HER2-Negative Metastatic Breast Cancer

Year: 2025

Type: supplementary-materials

Abstract: Supplementary Table S3 shows Treatment Emergent Adverse Events (TEAE) occurring in >10% of patients in the entire study (safety analysis set) by CTCAE grade (n = 27).

DOI: 10.1158/1078-0432.28227584

Authors: Jesus D. Anampa, Daniel L. Flynn, Cynthia Leary, Sun Oh, Xiaonan Xue, Maja H. Oktay, John S. Condeelis, Joseph A. Sparano

Language: English

Topic: Cancer Treatment and Pharmacology

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4406541190

Cites:

Cited by:

Related to: 10